Cel Sci (CVM) Total Current Liabilities (2010 - 2026)
Cel Sci (CVM) posted Total Current Liabilities of $4.8 million for Q1 2026, down 4.61% sequentially from $5.0 million in Q4 2025, and down 12.58% YoY from $5.5 million in Q1 2025.
Cel Sci (CVM) Total Current Liabilities (2010 - 2026) Analysis & Trends
Cel Sci has reported Total Current Liabilities for 16 years, with the latest figure at $4.8 million in Q1 2026.
- Quarterly Total Current Liabilities fell 12.58% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (down 12.58% YoY) and the FY2025 annual result came in at $5.1 million, up 11.15% from the prior year.
- Total Current Liabilities declined to $4.8 million in Q1 2026 per CVM's latest filing, from $5.0 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $5.6 million in Q2 2025 and troughed at $4.0 million in Q2 2022.
- A 5-year average of $5.0 million and a median of $5.1 million in 2024 frame the typical range for Total Current Liabilities.
- The widest YoY moves for Total Current Liabilities: up 42.25% in 2022, down 23.16% in 2022.
- Over 5 years, Total Current Liabilities stood at $4.7 million in 2022, then gained by 2.64% to $4.9 million in 2023, then grew by 12.58% to $5.5 million in 2024, then retreated by 8.01% to $5.0 million in 2025, then retreated by 4.61% to $4.8 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $4.8 million, $5.0 million, and $5.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | 5.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.81 Mn |
| Dec 31, 2025 | 5.04 Mn |
| Sep 30, 2025 | 5.13 Mn |
| Jun 30, 2025 | 5.62 Mn |
| Mar 31, 2025 | 5.50 Mn |
| Dec 31, 2024 | 5.48 Mn |
| Sep 30, 2024 | 4.62 Mn |
| Jun 30, 2024 | 5.51 Mn |
| Mar 31, 2024 | 5.09 Mn |
| Dec 31, 2023 | 4.87 Mn |
| Sep 30, 2023 | 5.59 Mn |
| Jun 30, 2023 | 5.29 Mn |
| Mar 31, 2023 | 5.31 Mn |
| Dec 31, 2022 | 4.74 Mn |
| Sep 30, 2022 | 4.66 Mn |
| Jun 30, 2022 | 4.02 Mn |
| Mar 31, 2022 | 4.47 Mn |
| Dec 31, 2021 | 3.33 Mn |
| Sep 30, 2021 | 3.94 Mn |
| Jun 30, 2021 | 5.16 Mn |